XML 71 R26.htm IDEA: XBRL DOCUMENT
v3.23.3

Organization and Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2023
Accounting Policies [Abstract] |
Schedule of Company's Current Pipeline | The following table presents the Company’s current pipeline:
Therapeutic Area | Name | Stage | Product Rights
Cardiometabolic | Plozasiran (ARO-APOC3) | Two Phase 2b and one Phase 3 | Arrowhead
| Zodasiran (ARO-ANG3) | Two Phase 2b | Arrowhead
| Olpasiran | Phase 3 | Amgen
Pulmonary | ARO-RAGE | Phase 1/2a | Arrowhead
| ARO-MUC5AC | Phase 1/2a | Arrowhead
| ARO-MMP7 | Phase 1/2a | Arrowhead
Liver | GSK-4532990 | Phase 2b | GSK
| Fazirsiran | Phase 3 | Takeda and Arrowhead
| JNJ-3989 | Phase 2 | Janssen(1)
| HZN-457 | Phase 1 | Horizon(2)
| ARO-C3 | Phase 1/2a | Arrowhead
| ARO-PNPLA3 | Phase 1 | Arrowhead
Muscle | ARO-DUX4 | Pre-Clinical | Arrowhead
Central Nervous System (CNS) | ARO-SOD1 | Pre-Clinical | Arrowhead
(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15. (2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.

X
- Definition Schedule of Current Products + References No definition available. + Details
Name: | arwr_ScheduleOfCurrentProductsTableTextBlock
Namespace Prefix: | arwr_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration